Dose finding with escalation with overdose control (EWOC) in cancer clinical trials (Q903293): Difference between revisions

@@ Property / MaRDI profile type @@
+MaRDI publication profile
@@ Property / MaRDI profile type: MaRDI publication profile / rank @@
+Normal rank
@@ Property / arXiv ID @@
+.6479
@@ Property / arXiv ID: 1011.6479 / rank @@
+Normal rank
@@ Property / cites work @@
+Optimal Bayesian-feasible dose escalation for cancer phase I trials
+Normal rank
@@ Property / cites work @@
+Coherence principles in dose-finding studies
@@ Property / cites work: Coherence principles in dose-finding studies / rank @@
+Normal rank
@@ Property / cites work @@
+Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
+Normal rank
@@ Property / cites work @@
+Unifying CRM and EWOC designs for phase I cancer clinical trials
+Normal rank
@@ Property / cites work @@
+Q5654899
@@ Property / cites work: Q5654899 / rank @@
+Normal rank
@@ Property / cites work @@
+Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
+Normal rank
@@ Property / cites work @@
+Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
+Normal rank
@@ Property / cites work @@
+TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
@@ Property / cites work: TWO-SAMPLE CONTINUAL REASSESSMENT METHOD / rank @@
+Normal rank
@@ Property / cites work @@
+Dose finding in drug development.
@@ Property / cites work: Dose finding in drug development. / rank @@
+Normal rank
@@ Property / OpenAlex ID @@
+W2952060368
@@ Property / OpenAlex ID: W2952060368 / rank @@
+Normal rank